BRPI0806492A2 - Uso de recombinases adaptadas ao tratamento de infecções retrovirais - Google Patents

Uso de recombinases adaptadas ao tratamento de infecções retrovirais

Info

Publication number
BRPI0806492A2
BRPI0806492A2 BRPI0806492-0A2A BRPI0806492A BRPI0806492A2 BR PI0806492 A2 BRPI0806492 A2 BR PI0806492A2 BR PI0806492 A BRPI0806492 A BR PI0806492A BR PI0806492 A2 BRPI0806492 A2 BR PI0806492A2
Authority
BR
Brazil
Prior art keywords
treatment
recombinases
retrovial
infections
genome
Prior art date
Application number
BRPI0806492-0A2A
Other languages
English (en)
Inventor
Joachim Hauber
Franz Buchholz
Ilona Hauber
Francis A Stewart
Indrani Sarkar
Original Assignee
Heinrich Pette Inst Univ Hamburg
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Heinrich Pette Inst Univ Hamburg filed Critical Heinrich Pette Inst Univ Hamburg
Publication of BRPI0806492A2 publication Critical patent/BRPI0806492A2/pt

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/63Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86Viral vectors
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/14Antivirals for RNA viruses
    • A61P31/18Antivirals for RNA viruses for HIV
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/10Processes for the isolation, preparation or purification of DNA or RNA
    • C12N15/1034Isolating an individual clone by screening libraries
    • C12N15/1058Directional evolution of libraries, e.g. evolution of libraries is achieved by mutagenesis and screening or selection of mixed population of organisms
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00Reverse transcribing RNA viruses
    • C12N2740/00011Details
    • C12N2740/10011Retroviridae
    • C12N2740/16011Human Immunodeficiency Virus, HIV
    • C12N2740/16041Use of virus, viral particle or viral elements as a vector
    • C12N2740/16043Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2800/00Nucleic acids vectors
    • C12N2800/30Vector systems comprising sequences for excision in presence of a recombinase, e.g. loxP or FRT

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Virology (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Bioinformatics & Computational Biology (AREA)
  • Ecology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • AIDS & HIV (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Enzymes And Modification Thereof (AREA)
BRPI0806492-0A2A 2007-01-08 2008-01-03 Uso de recombinases adaptadas ao tratamento de infecções retrovirais BRPI0806492A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP07100206A EP1942192A1 (en) 2007-01-08 2007-01-08 Use of a tailored recombinase for the treatment of retroviral infections
PCT/EP2008/000021 WO2008083931A1 (en) 2007-01-08 2008-01-03 Use of a tailored recombinases for the treatment of retroviral infections

Publications (1)

Publication Number Publication Date
BRPI0806492A2 true BRPI0806492A2 (pt) 2014-04-22

Family

ID=38179946

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0806492-0A2A BRPI0806492A2 (pt) 2007-01-08 2008-01-03 Uso de recombinases adaptadas ao tratamento de infecções retrovirais

Country Status (11)

Country Link
US (1) US8871516B2 (pt)
EP (2) EP1942192A1 (pt)
CN (1) CN101622356B (pt)
AT (1) ATE546540T1 (pt)
AU (1) AU2008204586B2 (pt)
BR (1) BRPI0806492A2 (pt)
CA (1) CA2674275C (pt)
ES (1) ES2379206T3 (pt)
RU (1) RU2501860C2 (pt)
WO (1) WO2008083931A1 (pt)
ZA (1) ZA200904561B (pt)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1942192A1 (en) 2007-01-08 2008-07-09 Heinrich-Pette-Institut für experimentelle Virologie und Immunologie Use of a tailored recombinase for the treatment of retroviral infections
US20110015256A1 (en) * 2009-07-16 2011-01-20 Ihab Mamdouh Ishak Sadek Delivery of restriction endonucleases to treat hiv, cancer, and other medical conditions
EP2576798B1 (en) 2010-05-27 2016-04-27 Heinrich-Pette-Institut Leibniz-Institut für experimentelle Virologie-Stiftung bürgerlichen Rechts - Tailored recombinase for recombining asymmetric target sites in a plurality of retrovirus strains
US12606824B2 (en) 2010-12-01 2026-04-21 Gowey Research Group, Pllc Micro-RNA profiling, compositions, and methods of treating diseases
WO2013173652A1 (en) * 2012-05-16 2013-11-21 Rana Therapeutics, Inc. Compositions and methods for modulating gene expression
BR112014028631A2 (pt) * 2012-05-16 2017-10-17 Rana Therapeutics Inc composições e métodos para modulação da expressão da família de genes da hemoglobina
CA2908253C (en) * 2013-04-04 2024-01-09 Trustees Of Dartmouth College Compositions and methods for in vivo excision of hiv-1 proviral dna
JP7118588B2 (ja) 2013-08-29 2022-08-16 テンプル ユニヴァーシティ オブ ザ コモンウェルス システム オブ ハイヤー エデュケイション Hiv感染のrnaガイド処置のための方法および組成物
EP2993229A1 (en) * 2014-09-02 2016-03-09 Heinrich-Pette-Institut Leibniz-Institut für experimentelle Virologie-Stiftung bürgerlichen Rechts - Well-tolerated and highly specific tailored recombinase for recombining asymmetric target sites in a plurality of retrovirus strains
RU2595373C1 (ru) * 2015-06-23 2016-08-27 Федеральное государственное бюджетное образовательное учреждение высшего образования "Саратовский государственный аграрный университет имени Н.И. Вавилова" Набор для выявления днк провируса иммунодефицита крупного рогатого скота, содержащий пару специфичных праймеров и зонд, и способ диагностики вирусного иммунодефицита крупного рогатого скота методом полимеразной цепной реакции в режиме реального времени
US10973930B2 (en) 2016-02-18 2021-04-13 The Penn State Research Foundation Generating GABAergic neurons in brains
CA3026332A1 (en) * 2016-06-03 2017-12-14 Temple University - Of The Commonwealth System Of Higher Education Negative feedback regulation of hiv-1 by gene editing strategy
EP3589307B1 (en) * 2017-02-28 2022-02-16 The Penn State Research Foundation Regenerating functional neurons for treatment of neural injury caused by disruption of blood flow
FI3638776T3 (fi) 2017-06-14 2025-12-09 Univ Dresden Tech Menetelmiä ja välineitä genomien geneettiseen muokkaamiseen hyödyntäen suunnittelu-DNA:ta rekombinoivia entsyymejä
EP3831939A1 (en) 2019-12-06 2021-06-09 Technische Universität Dresden Fusion of site-specific recombinases for efficient and specific genome editing
EP4433584A1 (en) 2021-11-15 2024-09-25 Technische Universität Dresden Site-specific recombinases for efficient and specific genome editing
CA3244685A1 (en) * 2021-12-28 2025-06-13 Jcr Pharmaceuticals Co., Ltd. Fusion protein of anti-transferrin receptor antibody and physiologically active protein for safe gene therapy
CN116492476A (zh) * 2022-12-06 2023-07-28 上海交通大学 细菌T6SS核心组分VgrG作为药物递送载体的构建方法
EP4424822A1 (en) 2023-02-28 2024-09-04 PROVIREX Genome Editing Therapies GmbH Designer recombinase for the precise excision of htlv-1-provirus

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2256972T3 (es) * 1997-11-18 2006-07-16 Pioneer Hi-Bred International, Inc. Metodo novedoso para la integracion de un adn foraneo dentro de genomas de eucariotas.
AR021056A1 (es) * 1998-11-03 2002-06-12 Syngenta Participations Ag Adn que comprende un gen especifico de antera de arroz y planta transgenica transformada con el mismo
US6890726B1 (en) * 1999-04-06 2005-05-10 Oklahoma Medical Research Foundation Method for selecting recombinase variants with altered specificity
FR2814642B1 (fr) * 2000-10-03 2005-07-01 Ass Pour Le Dev De La Rech En Souris transgenique pour la recombinaison ciblee mediee par la cre-er modifiee
GB0029375D0 (en) 2000-12-01 2001-01-17 Total Fina Elf Substrate linked directed evolution (slide)
US20040229335A1 (en) * 2003-05-15 2004-11-18 Introgen Therapeutics, Inc. Methods and compositions for the production of adenoviral vectors
EP1751180A4 (en) * 2004-02-26 2012-01-04 Israel State ENZYMES, CELLS, AND METHODS FOR LOCALLY-SPECIFIC RECOMBINATION AT ASYMMETRIC LOCATIONS
US20060014264A1 (en) * 2004-07-13 2006-01-19 Stowers Institute For Medical Research Cre/lox system with lox sites having an extended spacer region
EP1942192A1 (en) 2007-01-08 2008-07-09 Heinrich-Pette-Institut für experimentelle Virologie und Immunologie Use of a tailored recombinase for the treatment of retroviral infections

Also Published As

Publication number Publication date
RU2009130342A (ru) 2011-02-20
RU2501860C2 (ru) 2013-12-20
CA2674275C (en) 2015-10-20
WO2008083931A1 (en) 2008-07-17
EP2094855B1 (en) 2012-02-22
CA2674275A1 (en) 2008-07-17
AU2008204586B2 (en) 2011-08-11
CN101622356A (zh) 2010-01-06
EP2094855A1 (en) 2009-09-02
ZA200904561B (en) 2010-09-29
US20100172881A1 (en) 2010-07-08
EP1942192A1 (en) 2008-07-09
ES2379206T3 (es) 2012-04-23
AU2008204586A1 (en) 2008-07-17
CN101622356B (zh) 2013-09-25
ATE546540T1 (de) 2012-03-15
US8871516B2 (en) 2014-10-28

Similar Documents

Publication Publication Date Title
BRPI0806492A2 (pt) Uso de recombinases adaptadas ao tratamento de infecções retrovirais
WO2011147590A8 (en) Tailored recombinase for recombining asymmetric target sites in a plurality of retrovirus strains
Thomas et al. Nucleocapsid protein function in early infection processes
ATE527281T1 (de) Impfstoffe gegen aids umfassend cmv/r nucleinsäurekonstrukte
WO2007084435A8 (en) Methods for treating hepatitis c
SG178909A1 (en) Generation of a broad t-cell response in humans against hiv
EP4265299A3 (en) Therapeutic compounds useful for the prophylactic or therapeutic treatment of an hiv virus infection
WO2008133704A3 (en) Antimicrobial and antiviral compounds and methods for their use
WO2007022371A3 (en) Chemokine receptor binding compounds
MX2010009563A (es) Compuestos quimicos con accion antiviral contra virus de dengue y otros flavivirus.
CL2011002830A1 (es) Compuestos derivados de haloalquil heteroaril benzamidas; composicion farmaceutica uso de la composicion en el tratamiento de una infeccion viral, tal como el virus de la hepatitis b y c.
CA2862755A1 (en) Antiviral compounds with a dibenzooxaheterocycle moiety
NZ598000A (en) Composition for treating hbv infection
MX2009009473A (es) Compuestos para el tratamiento de hepatitis c.
WO2011132078A3 (en) Diagnosis of viral infections by detection of genomic and infectious viral dna by molecular combing
HK1207871A1 (en) Peptides derived from viral proteins for use as immunogens and dosage reactants
EA201390810A1 (ru) Жидкие вирусные составы
WO2005059107A3 (en) Chemokine receptor binding compounds
WO2006138259A3 (en) Chemokine receptor binding compounds
WO2013037841A3 (fr) Genomes lentiviraux chimeriques non- integratifs comme vaccins contre hiv-1
CA2556829C (en) Phosponate nucleosides useful as active ingredients in pharmaceutical compositions for the treatment of viral infections, and intermediates for their production
Carr et al. Isolation of a simian immunodeficiency virus from a malbrouck (Chlorocebus cynosuros)
PH12012501930A1 (en) Combination therapy comprising a ccr5 antagonist, a hiv-1 protease inhibitor and a pharmacokinetic enhancer
GB2463584A (en) Carbohydrate-lipid constructs and their use in preventing or treating viral infection
BRPI0514476A (pt) inibidores da formação de cápsideo hiv-1: aril aminometil tiazol uréias substituìdas e análogos destas

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 6A ANUIDADE. PAGAR RESTAURACAO.

B08H Application fees: decision cancelled [chapter 8.8 patent gazette]

Free format text: REFERENTE AO DESPACHO PUBLICADO NA RPI 2277 DE 26/08/2014

B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]

Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI

B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]

Free format text: MANTIDO O INDEFERIMENTO UMA VEZ QUE NAO FOI APRESENTADO RECURSO DENTRO DO PRAZO LEGAL